Lyell Immunopharma, Inc.LYELNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+49.6%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
+49.6%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
3.3x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 43.20% |
| 2024 | -45.24% |
| 2023 | -32.05% |
| 2022 | 12.91% |
| 2021 | -1.34% |
| 2020 | -107.60% |
| 2019 | 0.00% |